IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.

Abstract

PURPOSE:

IGF-I serum levels have been demonstrated as being associated with prostate cancer (PCa) and can serve as a predictive factor for the risk of PCa development. However, the role of IGF-II in PCa and its importance as a predictive marker is still unclear. Our aim was to determine PSA and IGF-II serum levels in patients with PCa and benign prostatic hyperplasia (BPH) and to analyse the value of IGF-II as an additional predictive factor in the diagnostics of PCa.

METHODS:

112 patients who underwent surgery for BPH or PCa (no hormonal treatment, no further malignancies) were included in this study ((I) 38 PCa, PSA < or = 15 ng/ml; (II) 34 PCa, PSA > 15 ng/ml; (III) 40 BPH). Preoperative serum levels of total PSA and total IGF-II were determined by ELFA and ELISA, respectively.

RESULTS:

PSA levels were (I) 5.7+/-1.9 ng/ml; (II) 25.0+/-11.5 ng/ml and (III) 4.0+/-2.8 ng/ml. (II) was statistically associated with a high grading (2b/3; p = 0.0182), a high Gleason sum score (7-10; p = 0.0049) and a non-organ confined tumor (T3/4; p = 0.0009) compared to (I), all Chi2 test. IGF-II levels were significantly higher in PCa (I+II) compared to BPH (833.8+/-238.9 ng/ml vs. 633.3+/-141.4 ng/ml, p < 0.0001, t-test). Both PSA and IGF-II were associated with tumor staging (p = 0.0097, p = 0.0308; t-test). No significant correlation was observed between PSA and IGF-II levels. Logistic regression analysis revealed that the combination of PSA and IGF-II improves the prediction of tumor staging in PCa (p = 0.0175 and p = 0.0459, Wald test). Additionally, the combination of PSA and IGF-II can significantly increase discrimination between BPH and PCa; each p < 0.0001, Wald test.

CONCLUSIONS:

This study provides evidence that IGF-II serum levels may serve as an additional parameter for (a) improved determination of tumor staging and (b) better discrimination between BPH and PCa.

• Authors: Lutz Trojan, Christian Bode, Christel Weiss, Doris Mayer, Rainer Grobholz, Peter Alken, Maurice Stephan Michel
• Journal: European urology (Eur Urol) Vol. 49 Issue 2 Pg. 286-92; discussion 292 (Feb 2006) ISSN: 0302-2838 [Print] Switzerland
• PMID: 16386354 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Biomarkers, Tumor
• Insulin-Like Growth Factor II
• Prostate-Specific Antigen

Topics

• Aged
• Aged, 80 and over
• Analysis of Variance
• Biomarkers, Tumor (blood)
• Diagnosis, Differential
• Humans
• Insulin-Like Growth Factor II (metabolism)
• Logistic Models
• Male
• Middle Aged
• Neoplasm Staging
• Predictive Value of Tests
• Prostate-Specific Antigen (blood)
• Prostatic Hyperplasia (blood, pathology)
• Prostatic Neoplasms (blood, pathology)
• ROC Curve